Earlier detection of bone loss may be in future

Earlier detection of bone loss may be in future

“Right now, pain is usually the first indication that cancer is affecting bones. If we could detect it earlier by an analysis of urine or blood in high-risk patients, it could significantly improve their care,” Fonseca said.

abstract + links/podcast: Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base

Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base

Conclusion 

Our phase III randomized placebo-controlled clinical trial demonstrated that naproxen at a dose of 500 mg twice per day is effective in reducing the incidence and severity of pegfilgrastim-induced bone pain.

Footnotes

• See accompanying editorial doi: 10.1200/JCO.2011.41.3146 and article doi: 10.1200/JCO.2011.39.2381;
  •  listen to the podcast by Dr Von Hoenn at www.jco.org/podcasts

Mayo Collaboration Finds Source of Breast Drug Side Effect - Drugs.com MedNews (aromatase inhibitors/arthritis/bone pain)

Mayo Collaboration Finds Source of Breast Drug Side Effect

Pharmacogenomic discovery allows for improved cancer therapy

ROCHESTER, Minn. — Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.


Read more: http://www.drugs.com/clinical_trials/mayo-collaboration-finds-source-breast-10214.html#ixzz10seG0Pnb